drugset / Trial / NCT06895499
Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.
Phase 1/2
Recruiting
15 enrolled
Shanghai Huaota Biopharmaceutical Co., Ltd.
Dermatology Hospital affiliated to Shandong First Medical University · collab
Non-randomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe HS.
Timeline
- Start
- 2025-03-19
- Primary completion
- 2026-01-30
- Completion
- 2026-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HB0043 | Monoclonal antibody | — | Intravenous |